JP2024540839A5 - - Google Patents
Info
- Publication number
- JP2024540839A5 JP2024540839A5 JP2024520702A JP2024520702A JP2024540839A5 JP 2024540839 A5 JP2024540839 A5 JP 2024540839A5 JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024540839 A5 JP2024540839 A5 JP 2024540839A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- alkyl
- kras
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252561P | 2021-10-05 | 2021-10-05 | |
| US63/252,561 | 2021-10-05 | ||
| PCT/US2022/045623 WO2023059598A1 (en) | 2021-10-05 | 2022-10-04 | Combination therapies of kras g12d inhibitors with shp-2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540839A JP2024540839A (ja) | 2024-11-06 |
| JP2024540839A5 true JP2024540839A5 (cg-RX-API-DMAC7.html) | 2025-10-10 |
Family
ID=85803689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520702A Pending JP2024540839A (ja) | 2021-10-05 | 2022-10-04 | Kras g12d阻害剤とshp-2阻害剤との併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240423984A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412719A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540839A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240073114A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118401254A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023059598A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| US20260200925A1 (en) * | 2021-11-24 | 2026-07-16 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras mutated proteins |
| EP4531846A4 (en) * | 2022-06-03 | 2026-05-27 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| WO2024012456A1 (zh) * | 2022-07-12 | 2024-01-18 | 南京明德新药研发有限公司 | 哌嗪桥取代的杂环并嘧啶类化合物 |
| KR20260074651A (ko) * | 2023-08-22 | 2026-05-26 | 사노피 | 암의 치료를 위한 kras g12d 억제제로서의 2-(3,8-디아자비시클로[3.2.1]옥탄-3-일)-1,3,5-트리아진 유도체 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| KR20260110993A (ko) | 2023-10-09 | 2026-07-14 | 인사이트 코포레이션 | Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| WO2026080796A1 (en) * | 2024-10-11 | 2026-04-16 | Mirati Therapeutics, Inc. | Mrtx1133 capsule pharmaceutical compositions |
| US20260137674A1 (en) | 2024-10-23 | 2026-05-21 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor |
| WO2026090333A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| US20240139193A1 (en) | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2022076917A1 (en) * | 2020-10-08 | 2022-04-14 | Kumquat Biosciences Inc. | Modulators of cell proliferation and uses thereof |
| US20240166669A1 (en) | 2021-03-05 | 2024-05-23 | Nikang Therapeutics, Inc. | Quinazoline amine derivatives as kras inhibitors |
| WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
-
2022
- 2022-10-04 EP EP22879176.0A patent/EP4412719A4/en active Pending
- 2022-10-04 US US18/694,921 patent/US20240423984A1/en active Pending
- 2022-10-04 KR KR1020247015004A patent/KR20240073114A/ko active Pending
- 2022-10-04 CN CN202280077626.5A patent/CN118401254A/zh active Pending
- 2022-10-04 JP JP2024520702A patent/JP2024540839A/ja active Pending
- 2022-10-04 WO PCT/US2022/045623 patent/WO2023059598A1/en not_active Ceased